As of today (2024-05-06), XenoPort's share price is $7.07. XenoPort's Tangible Book per Share of Mar. 2016 for the quarter that ended in Mar. 2016 was $0.12. Hence, XenoPort's Price to Tangible Book Ratio of today is 57.02.
The historical rank and industry rank for XenoPort's Price-to-Tangible-Book or its related term are showing as below:
XNPT's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.73 * Ranked among companies with meaningful Price-to-Tangible-Book only.
A closely related ratio is called PB Ratio. As of today, XenoPort's share price is $7.07. XenoPort's Book Value per Sharefor the quarter that ended in Mar. 2016 was $0.12. Hence, XenoPort's P/B Ratio of today is 57.02.
XenoPort Price-to-Tangible-Book Historical Data
The historical data trend for XenoPort's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of XenoPort's Price-to-Tangible-Book
For the Biotechnology subindustry, XenoPort's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XenoPort's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XenoPort's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where XenoPort's Price-to-Tangible-Book falls into.
XenoPort Price-to-Tangible-Book Calculation
XenoPort's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
XenoPort Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of XenoPort's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
XenoPort Inc is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological and other disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which it may commercialize its products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XNPT has been successfully added to your 